Selegiline in de novo parkinsonian patie
β
Prof. V. V. MyllylΓ€; K. A. Sotaniemi; J. A. Vuorinen; E. H. Heinonen
π
Article
π
1993
π
John Wiley and Sons
π
English
β 353 KB
Selegiline (L-deprenyl) has been recommended as an antiparkinsonian drug to be used as an adjunct to therapy with L-dopa, if and when L-dopa starts to lose its effect. However, initial selegiline monotherapy followed by L-dopa may be both effective and safe. A double-blind, placebo-controlled trial